“Do you see what I see?”

No Comments on “Do you see what I see?”

Investigator Meeting in Hamburg

Dr. Wolfgang Brysch welcomes the Investigators

Dr. Wolfgang Brysch welcomes the Investigators
Photo: © Eva Brysch, 2018

 

The MetrioPharm team in Hamburg

The MetrioPharm team in Hamburg
Photo: © Eva Brysch, 2018

“Do we all see the same thing in this picture, exactly the same? And why is that so crucial?” That’s what we asked at our Investigator Meeting in Hamburg, where employees of MetrioPharm and our study partner Bioskin met the Investigators (trial physicians) and the study nurses who will conduct our Phase II clinical trial.

Only a stone’s throw away from the new Elbphilharmonie concert hall we discussed all important questions concerning the upcoming trial: Which patients will be included? In what way will the drugs be administered? How will the treatment be documented?

Documentation, in particular, will play a central role in the success of the trial, because MP1032’s treatment success must be measurable and classifiable. In the current study, we are assessing MP1032 in the indication psoriasis. The most important criterion for success is a clear improvement in rashes.

In order to objectively measure such an improvement, dermatologists use, among others, the PASI index. Symptoms in different parts of the body are evaluated in four categories and a PASI score is calculated from these measurements. It is crucial that the participating physicians evaluate similar symptoms and their changes in the same way. This is the only way to achieve reliable results for the study.

For practice, we had a PASI quiz at our Investigator Meeting to make sure that everyone will see the same thing in the coming trial – exactly the same.

Phase II study material for the study sites

Phase II study material for the study sites
Photo: © Eva Brysch, 2018

After an intensive weekend we would like to thank all participants. In discussions with dermatologists, we were once again reminded of the urgent need for an easily available and side-effect-reduced drug for the treatment of psoriasis in everyday practice. This meeting has motivated us very much for the coming challenges!

We were also pleased to receive good feedback on the previous findings for MP1032 and look forward to working together on the Phase II clinical trial.

Leave a Reply

Your email address will not be published. Required fields are marked *